Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection

Journal of Medical Virology

Volumn 90, Issue 2, 2018, Pages 367-371

  Trivedi, Suvang ^a   Miao, Congrong ^b   Al Abdallat, Mohammad M ^c   Haddadin, Aktham ^c   Alqasrawi, Sultan ^c   Iblan, Ibrahim ^d   Nsour, Mohannad A ^e   Alsanouri, Tarek ^c   Ali, Sami S ^c   Rha, Brian ^b   Gerber, Susan I ^b   Payne, Daniel C ^b   Tamin, Azaibi ^b   Thornburg, Natalie J ^b  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Jordan Ministry of Health   (Jordan)

^d CDC   (Jordan)

^e Eastern Mediterranean Public Health Network   (Jordan)

Author keywords

antibodies; coronaviruses; immunity; MERS CoV; serology; surveillance

Indexed keywords

NUCLEOCAPSID PROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY; CORONAVIRUS SPIKE GLYCOPROTEIN;

ALGORITHM; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; SEROLOGY; VALIDATION PROCESS; VIRUS IDENTIFICATION; VIRUS TITRATION; WESTERN BLOTTING; BLOOD; CORONAVIRUS INFECTION; IMMUNOLOGY; PROCEDURES;

ALGORITHMS; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SEROLOGIC TESTS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85037691351     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24948     Document Type: Article

References (19)

1. Middle East respiratory syndrome coronavirus (MERS-CoV). 2017, 2017.
2. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014; 59:1225–1233.
3. Chan JF, Sridhar S, Yip CC, Lau SK, Woo PC. The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic. J Microbiol. 2017; 55:172–182.
4. Hemida MG, Perera RA, Al Jassim RA, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill. 2014; 19:pii 20828.
5. Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014; 194:175–183.
6. Muth D, Corman VM, Meyer B, et al. Infectious middle east respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol. 2015; 53:2951–2955.
7. Park WB, Perera RA, Choe PG, et al. Kinetics of serologic responses to MERS Coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015; 21:2186–2189.
8. Muller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015; 15:629.
9. Park SW, Perera RA, Choe PG, et al. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. Euro Surveill. 2015; 20:pii 30042.
10. Kapoor M, Pringle K, Kumar A, et al. Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States. Clin Infect Dis. 2014; 59:1511–1518.
11. Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against middle east respiratory syndrome coronavirus. Emerg Infect Dis. 2016; 22:1824–1826.
12. Greiner M. Two-graph receiver operating characteristic (TG-ROC): a Microsoft-EXCEL template for the selection of cut-off values in diagnostic tests. J Immunol Methods. 1995; 185:145–146.
13. Greiner M, Sohr D, Gobel P. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods. 1995; 185:123–132.
14. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013; 67:130–140.
15. Wang W, Wang H, Deng Y, et al. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg Microbes Infect. 2016; 5:e113.
16. Ko JH, Muller MA, Seok H, et al. Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests. Eur J Clin Microbiol Infect Dis. 2017;epub ahead of print.
17. Tan YJ, Goh PY, Fielding BC, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol. 2004; 11:362–371.
18. Woo PC, Lau SK, Wong BH, et al. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol. 2005; 43:3054–3058.
19. Agnihothram S, Gopal R, Yount BL, Jr., et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014; 209:995–1006.